• Cantel Medical (Little Falls, New Jersey), said that as part of its plan to expand its infection prevention and control business, it has acquired Crosstex International (Hauppauge, New York), a manufacturer and reseller of single-use infection control products used broadly in the healthcare arena, principally in the dental market. The purchase price was $74.2 million, comprised of $67.4 million in cash and 384,821 shares of Cantel stock (valued at $6.8 million). There is a further $12 million potential earnout payable to the sellers over three years based on operating results.

• dj Orthopedics (San Diego), a company specializing in rehabilitation and regeneration products for the non-operative orthopedic and spine markets, said it has purchased the assets of the orthopedics soft goods (OSG) business of Encore Medical (Aus-tin, Texas) for about $10 million in cash. The transaction was structured as an asset purchase and included certain tangible and intangible assets of the OSG business, including inventory, certain fixed assets and intellectual property. The OSG product lines consist of orthopedic soft goods, patient safety products and pressure care products.

• HealthTronics (Austin, Texas) reported the sale of its orthopedic electrocorporeal shockwave litho-tripsy (ESWL) assets to SanuWave (Marietta, Georgia), a privately held company established by Prides Capital (Boston/San Francisco), for $10.4 million. The purchase price is payable in the form of $6.4 million of cash at closing and of $4 million long-term promissory notes. SanuWave provides non-invasive surgical solutions for orthopedic conditions such as chronic plantar fasciitis and chronic lateral epicondylitis, better known as heel pain and tennis elbow.

• Hospital products manufacturer Hospira (Lake Forest, Illinois) reported completing its purchase of Physiometrix (North Billerica; Massachusetts), a developer of non-invasive medical devices, for about $23 million in cash, plus repayment of about $1 million in bank debt. The acquisition was first unveiled in June. The Physiometrix portfolio includes the PSA 4000, a real-time EEG, or brain-state monitor, that aids in evaluating the effects of anesthetic agents; and the SEDLine monitor (previously known as the PSA 5000), a next-generation platform.

• MicroMed Technology (Houston), a developer of miniaturized implantable ventricular assist technology, reported completing its previously announ-ced merger with a wholly owned subsidiary of Sal-mon Express (Vernon, British Columbia). The combined company has been renamed MicroMed Cardiovascular. In connection with the deal, MicroMed completed an equity financing through a private placement of $5 million of common stock by Hunter World Markets (Beverly Hills, California). MicroMed’s initial platform in heart failure products is the DeBakey Ventricular Assist Device (VAD) for the treatment of advanced heart failure.

• NuVasive (San Diego), which is focused on developing products for minimally disruptive surgical treatments for the spine, reported that it has ac-quired technology and assets from privately owned Pearsalls (Taunton, UK), related to that company’s nucleus-like replacement device called the Neodisc, as well as all of that company’s intellectual property related to embroidery technology for use in surgical implants. The transaction requires a closing payment by NuVasive of $12 million, including $5 million in cash and $7 million in stock. NuVasive will make additional payments upon the achievement of certain milestones leading to FDA approval that could total up to an additional $31.5 million in cash and stock. It also will pay a royalty of 5% on sales of the Neodisc product.

• Ostara (Wernersville, Pennsylvania) reported acquiring majority control of Rheologics (Exton, Pennsylvania), a company studying the dynamics of blood flow and its impact on vascular-related and other diseases. Ostara said it has acquired more than 90% of Rheologics’ shares. Ostara said it plans to use the Rheologics acquisition to help drive the company toward emerging medical technologies.

• Quest Diagnostics (Lyndhurst, New Jersey) reported that it has signed a definitive agreement to acquire LabOne (Lenexa, Kansas) in a deal valued at $934 million. The proposed deal has been unanimously approved by both companies’ boards of directors. Quest will acquire all outstanding common shares of LabOne for $43.90 a share in an all-cash transaction. The deal value also factors in assumption of $132 million of LabOne’s convertible debt.

• Philips Medical Systems (Andover, Massachusetts) reported that it has completed the $280 million acquisition of Stentor (Brisbane, California), a provider of picture archiving and communication systems (PACS). Philips first disclosed its intention to acquire Stentor in July.

• WorldHeart (Oakland, California) reported the completion of its acquisition of MedQuest Products (Salt Lake City), which in the development stages of its HeartQuest ventricular assist device (VAD). WorldHeart issued 9.3 million common shares to MedQuest in connection with the acquisition. In conjunction with the deal, the company raised about $23 million in gross financing from a private placement with Maverick Venture Management and the exercise of certain outstanding warrants for the purchase of common shares.